Abstract Library

#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients

Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K,

Keywords: neuroendocrine tumors, PET, Al18F-NOTA-octreotide, 68Ga-DOTATATE, somatostatin receptor imaging,

#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast

Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,

Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,

#2717 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms

Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carlsen E

Authors: Carlsen E, Johnbeck C, Binderup T, Loft M, Pfeifer A,

Keywords: 64Cu-dotatate, neuroendocrine neoplasm, progression-free survival, overall survival,

#1874 Value of Somatostatin Receptor Imaging (SRI) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Base on Clinical Follow-Up

Introduction: Neuroendocrine neoplasms of the appendix are common GEP-NEN tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Konsek S, Kolasińska-Ćwikła A, Lewczuk A, Kidd M, Cichocki A,

Keywords: neuroendocrine neoplasm, appendiceal neuroendocrine neoplasm, somatostatin receptor scintigraphy,

#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Severi S, Drozdov I, Nicolini S,

Keywords: NETest, PRRT,